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A B S T R A C T
Background and objectives: Circadian rhythms contribute to treatment efficacy in several non-communicable diseases. However,
chronotherapy (administering drugs at a particular time-of-day) against infectious diseases has been overlooked. Yet, the daily rhythms
of both hosts and disease-causing agents can impact the efficacy of drug treatment. We use the rodent malaria parasite Plasmodium
chabaudi, to test whether the daily rhythms of hosts, parasites and their interactions affect sensitivity to the key antimalarial,
artemisinin.
Methodology: Asexual malaria parasites develop rhythmically in the host’s blood, in a manner timed to coordinate with host daily
rhythms. Our experiments coupled or decoupled the timing of parasite and host rhythms, and we administered artemisinin at different
times of day to coincide with when parasites were either at an early (ring) or later (trophozoite) developmental stage. We quantified
the impacts of parasite developmental stage, and alignment of parasite and host rhythms, on drug sensitivity.
Results: We find that rings were less sensitive to artemisinin than trophozoites, and this difference was exacerbated when parasite and
host rhythms were misaligned, with little direct contribution of host time-of-day on its own. Furthermore, the blood concentration of
haem at the point of treatment correlated positively with artemisinin efficacy but only when parasite and host rhythms were aligned.
Conclusions and implications: Parasite rhythms influence drug sensitivity in vivo. The hitherto unknown modulation by alignment be-
tween parasite and host daily rhythms suggests that disrupting the timing of parasite development could be a novel chronotherapeutic
approach.
Lay Summary: We reveal that chronotherapy (providing medicines at a particular time-of-day) could improve treatment for malaria
infections. Specifically, parasites’ developmental stage at the time of treatment and the coordination of timing between parasite and
host both affect how well antimalarial drug treatment works.
K E Y W O R D S : chronotherapy; malaria; Plasmodium; artemisinin; circadian; drug sensitivity
INTRODUCTION
That circadian rhythms affect drug treatment outcomes (includ-
ing the alleviation of symptoms and/or severity of side effects)
has been known for decades. Chronotherapeutic approaches
aim to optimise the timing of drug administration by consider-
ing how daily changes in gene expression and physiology influ-
ence the absorption, metabolism, toxicity and half-life of drugs,
the availability of drug targets, and co-active immune effectors
[1]. For example, lipid-lowering medications are taken at night
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to coincide with the daily peak in cholesterol biosynthesis,
rheumatoid arthritis is treated at night to minimise morning
symptoms, and daily rhythms may affect the efficacy and toxicity
of some cancer drugs (reviewed in [2]). With most best-selling
human medicines targeting products of genes with daily rhyth-
micity, chronotherapy could optimise the use of many drugs [3].
Chronotherapy is mostly used against non-communicable dis-
eases. Yet, timing drug treatment according to rhythms exhib-
ited by hosts and/or parasites [4–6] could optimise drug
bioavailability and half-life, minimise drug toxicity and coordin-
ate with immune rhythms to enhance parasite removal [7–9].
Parasite rhythms are suspected to affect drug sensitivity dur-
ing malaria infections. Most species of malaria (Plasmodium)
parasites replicate synchronously in the host’s blood, with the
duration of the intra-erythrocytic developmental cycle (IDC) tak-
ing multiples of 24 h depending on the species (reviewed in
[10]). The IDC comprises sequential morphologically, transcrip-
tionally and metabolically divergent developmental stages, and
multiple antimalarials show stage-specific efficacy (e.g. [11,
12]). Determining which IDC stage is most vulnerable to treat-
ment is especially useful for drugs with short half-lives [13],
such as artemisinin derivatives [14, 15], which are currently
used in combination therapy as first-line treatment for malaria.
There is considerable variation in stage-specific sensitivity to ar-
temisinin across studies (Table 1). Conflicting results may be
due to variation between experimental set-ups, including differ-
ences in artemisinin derivatives, parasite species and geno-
types, and the ages of IDC stages tested (e.g. young or old
rings). Furthermore, in vitro and in vivo studies may yield differ-
ent outcomes because host rhythms are likely to directly, and/
or via interactions with parasite rhythms, affect drug efficacy.
However, in vivo studies often confound IDC stage and host
time-of-day at the point of treatment. For example, if a treat-
ment seems most efficacious at dawn, it is unclear whether this
is due to the effects of host time-of-day on drug metabolism,
and/or corresponds to parasites being at a particularly vulner-
able IDC stage. As parasite and host rhythms may not always
align, knowing whether chronotherapy should be organised
around host and/or parasite time is essential. Furthermore, the
alignment between host and parasite rhythms itself may be a
key determinant of treatment efficacy at different times of day.
Understanding the relative contributions of host and parasite
rhythms to antimalarial efficacy could resolve the disconnect be-
tween in vitro efficacy tests and in vivo treatment outcomes, re-
veal how temporary arrest (quiescence) at certain IDC stages
confers tolerance to antimalarials and allow malaria treatment
to be optimised by chronotherapy. Here, we use the rodent mal-
aria parasite Plasmodium chabaudi to investigate whether both
host and parasite rhythms contribute to antimalarial efficacy.
We used the short-acting drug artemisinin to test for proof-of-
principle, whilst acknowledging the ongoing importance of arte-
misinin-based therapies in malaria management. By manipulat-
ing whether IDC rhythms are aligned with host rhythms or not,
and treating infections at different times of day with artemisi-
nin, we tested whether drug efficacy depends on the parasite’s
IDC stage, host time-of-day or their interaction. Additionally, we
assessed putative correlates (haem and blood glucose concen-
tration) of host rhythms and drug efficacy. Haem is an essential
molecule for IDC progression, which parasites can biosynthe-
sise, or scavenge from host haemoglobin [46]. Intracellular
haem activates artemisinin [21, 47], and both haemoglobin con-
centration [4] and the rate of haem synthesis in red blood cells
(RBCs) are under circadian control [48]. Thus, daily variation in
haem levels could affect pharmacokinetics, with the expectation
that artemisinin efficacy is boosted when haem levels are high.
Blood glucose concentration also oscillates daily [49] and is a
vital resource for parasites [50], suggesting parasites may be
more sensitive to drugs when glucose concentration is low.
Table 1. Previous research on the stage specificity of artemisinin derivatives in drug-sensitive parasites
References
Rings vs older IDC stagesa
No stage specificity observed [12, 16–20]
Early IDC stages less sensitive than older IDC stages [11, 17, 19, 21, 22–37]
Early IDC stages more sensitive than older IDC stagesb [16, 20, 33, 34, 37–44]
Early vs late rings
Early rings more sensitive than late rings [16, 27, 32, 33]
Early rings similarly sensitive as late rings [42, 45]
Early rings less sensitive than late rings [34]
aOlder IDC stages include trophozoites and/or schizonts.
bMany of these studies use the schizont maturation test (incubation of parasites with drugs until a certain percentage of parasites in control wells
matures into schizonts), in which the duration of drug treatment is longer for the early IDC stages and thus is confounded with stage specificity.
In contrast to many other antimalarial drugs, artemisinins also target the early intra-erythrocytic developmental cycle (IDC) stages (‘rings’) of
Plasmodium parasites, but studies report inconsistent results regarding the relative sensitivity of rings versus older IDC stages.
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We reveal that parasites early in their IDC (rings) are less sen-
sitive to artemisinin than mid-IDC parasites (trophozoites).
Host time-of-day did not directly affect drug efficacy but the co-
ordination between parasite and host rhythms did. Specifically,
when the timing of the IDC was misaligned (mismatched) with
host rhythms, rings exhibited even lower drug sensitivity and
trophozoites became more sensitive. Whereas glucose levels
did not correlate with drug efficacy, haem concentration at the
point of treatment correlated positively with drug efficacy, but
only in matched infections.
METHODOLOGY
We carried out two experiments to test whether host and para-
site rhythms affect artemisinin efficacy. The first experiment
revealed intra-erythrocytic developmental cycle (IDC)-stage-spe-
cific efficacy and suggested an impact of host time-of-day. The
second experiment tested whether the apparent role of host
time-of-day was better explained by the alignment between
parasite and host rhythms.
Parasites and hosts
We used the synchronous species P. chabaudi chabaudi (geno-
type CW) originally isolated from Grammomys poensis (previously
called Thamnomys rutilans). Hosts were 7- to 11-week-old male
C57BL/6 mice which had access to food ad libitum and drinking
water was supplemented with 0.05% para-aminobenzoic acid
[51]. Mus musculus is a natural host for some rodent malaria spe-
cies [52]. All mice were kept in photoschedules of 12 h light-12 h
dark, although the time-of-day at which lights went on/off varied
between treatment groups within each experiment (Fig. 1). Mice
were acclimatised (entrained) to their respective photoschedules
for at least two weeks before infections. All procedures occurred
in accordance with the UK Home Office regulations (Animals
Scientific Procedures Act 1986; project licence number 70/8546)
and were approved by the University of Edinburgh.
Experimental design
Both experiments followed the same general set-up. We
expanded cryopreserved parasites through 2–3 passages in
donor mice kept in a 12 h light–12 h dark photoschedule (lights
on: 7 am, lights off: 7 pm). This ensured parasites’ IDC sched-
ule was aligned with host rhythms. To initiate experimental
infections, we diluted blood from donor mice in citrate saline
(0.85% w/v NaCl, 1.5% w/v trisodium citrate dihydrate) and
passaged parasites by intravenous injection of ring stage
infected red blood cells (iRBCs) into two groups of experimental
mice simultaneously. One group of experimental mice were in
the same photoschedule as the donor mice (lights on: 7 am,
lights off: 7 pm), so that parasite and host rhythms were aligned
in experimental hosts (‘matched’ infections). The other group
of experimental mice was in the opposite photoschedule (lights
on: 7 pm, lights off: 7 am), such that parasites transferred from
donor to experimental mice experienced an instantaneous 12-h
shift in host time-of-day (causing misaligned, ‘mismatched’
infections) (Fig. 1A). To ensure all hosts were infected from the
same pool of parasites, we initiated experimental infections at 7
am; when lights went on for recipients of matched infections
(Zeitgeber Time 0, ZT0), and at lights off for hosts of mis-
matched infections (ZT12) (Fig. 1A). We split both matched
and mismatched infections into two groups that received drug
treatment when parasites were either rings or trophozoites (as
determined by microscopy), creating four treatment groups
(Fig. 1B–C). Stage distributions at the time of treatment did not
differ between matched and mismatched infections
(Supplementary Table S1). Treated infections received a sub-
curative dose of 50 mg/kg artemisinin (Alfa Aesar) dissolved in
50ml dimethyl sulphoxide (DMSO) and administered by intra-
peritoneal injection. The short elimination half-life of artemisi-
nin (23 min) [15] ensured that only the intended IDC stage
was exposed to treatment. Placebo-treated control mice
received 50ml DMSO intraperitoneally when parasites were
rings. Mismatched parasites reschedule to coordinate with their
host’s feeding rhythms within a few IDCs [49, 53, 54]. Therefore,
to minimise the extent of rescheduling in mismatched para-
sites, we administered drug treatment early in the infection and
initiated infections with high parasite doses to ensure densities
were high enough for accurate quantification.
Experiment 1
We initiated infections (n¼ 40) with 108 ring stage iRBCs and
drug treated on Day 2 post infection (p.i.). At this point, the
IDC of mismatched parasites was misaligned to host rhythms
by 7 h (Fig. 1B). Based on this schedule, we administered arte-
misinin or placebo during the period of ring stage development
(ZT20 for n¼ 8 matched infections and n¼ 4 matched controls,
and ZT3 for n¼ 8 mismatched infections and n¼ 4 mismatched
controls), or during the trophozoite stage (ZT8 for n¼ 8
matched infections and ZT15 for n¼ 8 mismatched infections)
(Fig. 1B). We took blood samples from the tail vein just prior to
drug administration (t0) to quantify parasites and measure
haem and glucose levels, and also quantified parasites after
24 h (t24). We quantified parasites from 5-ml blood samples
using a semi-automatic Kingfisher Flex Magnetic Particle
Processor and MagMAXTM-96 DNA Multi-Sample Kit (Thermo
Fisher Scientific) with slight modifications from the standard
protocol 4413021DWblood [55] and enumerated parasite
genomes using qPCR targeting the CG2 gene
(PCHAS_0620900, previously named PC302249.00.0) [56]. We
measured blood glucose concentration using an Accu-CheckV
R
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Performa Nano device (Roche). For the haem assay (Heme
Assay Kit, Sigma-Aldrich), absorbance was measured at 405 nm
using a Multiskan Ascent 96/384 Plate Reader (MTX Lab
Systems) in a single plate, following manufacturer’s instruc-
tions. We were unable to measure one haem sample (rings,
matched infection).
Experiment 2
The aim of the first experiment was to target rings and tropho-
zoites in both matched and mismatched infections. This
resulted in parasites in matched and mismatched infections
being treated at times coupled to their hosts’ active or resting
phase (Fig. 1B). Therefore, a difference in the sensitivity of rings
in matched versus mismatched infections could be driven sim-
ply by physiological differences between matched and mis-
matched parasites [57], and/or by the effects of treating hosts
in their active versus resting phase. Thus, Experiment 2 was
designed such that we treated each IDC stage in the same host
phase for both matched and mismatched infections. To achieve
this, we initiated infections (n¼ 30) at a 10-fold lower parasite
density (107 ring stage iRBCs) than Experiment 1, followed by
drug treatment on Day 3 p.i. This allowed mismatched parasites
an additional IDC to reschedule, so that parasite and host
rhythms in mismatched infections were only misaligned by
4 h at t0. Therefore, each IDC stage could be treated in the
same host phase across matched and mismatched infections
(Fig. 1C). Specifically, rings were treated in the active (dark)
phase (ZT16 for n¼ 5 matched infections and n¼ 5 matched
controls, and ZT20 for n¼ 5 mismatched infections and n¼ 5
mismatched controls), and trophozoites were treated in the
resting (light) phase (ZT8 for n¼ 5 matched infections and
ZT11.5 for n¼ 5 mismatched infections) (Fig. 1C). We took
blood samples from the tail vein at t0 and t24. In contrast to
Experiment 1, parasite densities were high enough for accurate
quantification by microscopy. Thus, we calculated parasite den-
sities by multiplying RBC densities as measured by flow cytome-
try (Beckman–Coulter counter) and determined the proportion
of iRBCs by microscopic counting from thin blood smears












































































Figure 1. Experimental designs. Ring stage parasites were transferred from donor mice into recipient mice housed in the same photoschedule (host and para-
site rhythms aligned: ‘matched’) or recipients housed in the reverse photoschedule (host and parasite rhythms misaligned: ‘mismatched’). Approximate tim-
ings when parasite IDC stages are abundant in the blood are indicated by infected red blood cells. (A). Due to rescheduling of parasites to the rhythms of
their new hosts, parasite stages at the time of drug administration were misaligned from their host’s schedule by 7 and 4 h in experiments 1 (B) and 2 (C),
respectively. Syringes indicate the treatment time for rings (R) and trophozoites (T), grey shading indicates lights off (i.e. mouse active phase). Note: artemisi-
nin is a rapidly acting drug, with an elimination half-life of 23 min in mice [15].
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Statistical analysis
Data were analysed with R v.3.6.3 (R Foundation for Statistical
Computing, Vienna, Austria, https://www.R-project.org/) using
the base R system unless otherwise indicated. To assess any
differences between treatment groups at t0, we compared para-
site densities, as well as glucose and haem levels for
Experiment 1, between treatment groups using linear models
with IDC ‘Stage’ (rings or trophozoites), ‘Alignment’ (matched
or mismatched infections) and their interaction as explanatory
variables. Parasite densities were log10-transformed to meet
assumptions of normality and homogeneity of variance.
Because the time-of-day of drug administration varied between
groups, parasites in some groups had gone through an add-
itional part-cycle of replication, resulting in differences in para-
site densities at t0 (Supplementary Table S2 and Fig. S1). To
correct for this, we analysed relative change (DParDensrel(t0,
t24)) by fitting parasite density at t24 (ParDens(t24)), in linear
models including an offset for parasite density at t0
(ParDens(t0)). Results are presented as the corresponding fold
change:




A relative change of 1 means that parasite densities were
identical at t0 and t24, a decrease is indicated by <1, and an in-
crease by >1. Note: values >1 in artemisinin-treated groups do
not indicate that drugs were ineffective, merely that after drug
treatment, parasites replicated to higher densities than they
were at t0.
To confirm artemisinin-treated infections had fewer parasites
than placebo-treated controls regardless of whether infections
were matched or mismatched, we tested a linear model includ-
ing the terms ‘Drug’ (drug-treated or placebo-treated infec-
tions), ‘Alignment’ (matched or mismatched infections) and
their interaction (Supplementary Table S3, Fig. 2A–B). To test
our hypothesis that drug efficacy depends on IDC stage and
alignment of host and parasite rhythms, linear models included
the terms ‘Stage’ (rings or trophozoites), ‘Alignment’ (matched
or mismatched infections) and their interaction as explanatory
variables (plus haem or glucose levels for Experiment 1). For
Experiment 1, we also constructed models using the term
‘Phase’ (host active or resting phase) instead of ‘Alignment’
(matched or mismatched infections) to test whether alignment
or host phase best explained drug efficacy. We minimised
nested models using maximum likelihood deletion tests, for
which we report test statistics and P-values. We compared non-
nested models by Akaike Information Criteria (corrected)
(AICc) for small sample sizes; ‘MuMIn’ package). We report
results for the minimally adequate models in the main text, and
full statistical outcomes in Tables 2–3 and Supplementary
Tables S2–S5. We present predictions of drug efficacy according
to haem levels at t0 based on the minimised model shown in
Table 2B with a variation in haem concentrations ranging from
2.9 to 10.4 mM in 0.01 steps, and parasite density at the time of
treatment set to the mean for each of the four treatment
groups.
RESULTS
Assumptions of the experimental design
Parasites were treated at either ring or trophozoite stage and,
as expected, the intended intra-erythrocytic developmental cycle
(IDC) stage predominated in the blood in all treatment groups
just prior to treatment (t0) (Supplementary Table S1). Because
we administered treatment to specific IDC stages, parasite den-
sities at t0 differed between treatment groups (Experiment 1,
Stage  Alignment interaction: F(1,28) ¼ 5.48, P¼ 0.027;
Experiment 2, Stage  Alignment interaction: F(1,17) ¼ 1.90,
P¼ 0.187, Stage: F(1,18) ¼ 11.14, P¼ 0.004) (Supplementary
Table S2 and Fig. S1). This confirms the need to measure drug
efficacy as the relative change in parasite density from 0 to 24 h
post artemisinin treatment (DParDensrel(t0, t24)).
In both experiments, artemisinin-treated infections had lower
relative parasite densities than placebo-treated controls
(Experiment 1, Drug: F(1,38) ¼ 29.94, P< 0.001; Experiment 2,
Drug: F(1,28) ¼ 28.64, P< 0.001) (Supplementary Table S3).
Specifically, parasite densities increased in placebo-treated
infections (mean DParDensrel(t0, t24) 6 SEM 4.22 6 0.93 for
matched and 3.54 6 1.64 for mismatched infections in
Experiment 1, and 1.47 6 0.18 for matched and 1.65 6 0.07 for
mismatched infections in Experiment 2). In contrast, parasite
densities decreased or remained unchanged in artemisinin-
treated infections (mean DParDensrel(t0, t24) 6 SEM
0.52 6 0.10 for matched and 0.98 6 0.30 for mismatched infec-
tions in Experiment 1, and 0.44 6 0.05 for matched and
0.50 6 0.12 for mismatched infections in Experiment 2)
(Fig. 2A–B).
Impact of host and parasite rhythms on drug efficacy
Drug efficacy (DParDensrel(t0, t24)) in Experiment 1 varied sig-
nificantly according to whether we treated rings or trophozoites
and whether host and parasite rhythms were aligned
(StageAlignment interaction: F(1,28) ¼ 10.19, P¼ 0.003)
(Table 2A). In matched infections, rings were less sensitive to
artemisinin than trophozoites (mean DParDensrel(t0, t24) 6
SEM 0.69 6 0.18 for matched rings and 0.35 6 0.07 for matched
trophozoites). When parasite and host rhythms were mis-
matched, drug efficacy was enhanced for trophozoites and



















































Matched rings treated in active phase
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Rings treated in active phase
Trophozoites treated in resting phase
Matched rings treated in active phase
Matched trophozoites treated in resting phase
Mismatched trophozoites treated in resting phase
Mismatched rings treated in active phase
Matched
Mismatched
Figure 2. Effects of artemisinin drug treatment on parasite density. Relative change in parasite densities from 0 to 24 h post treatment (DParDensrel(t0, t24)) in
Experiment 1 (A, C, D) and Experiment 2 (B, E, F). The horizontal dashed lines indicate no change in parasite density over time. Data represent the mean 6
SEM. (A, B) Parasites were treated with placebo or artemisinin in matched (diamonds, solid lines) and mismatched infections (squares, dashed lines). All ar-
temisinin-treated infections are combined regardless of which parasite stage was treated. (C-F) Parasites were treated as rings (red circles) or trophozoites
(blue triangles), during the host’s active phase/dark (closed symbols) or resting phase/light (open symbols). Note: (D) and (F) are replotted versions of (C)
and (E), respectively, to highlight the interaction between Alignment and Stage. (G) Heatmap indicating predicted DParDensrel(t0, t24) according to haem lev-
els. Increasing parasite densities are shown in purple, decreasing parasite densities are shown in yellow, with white indicating no change.
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weakened for rings (mean DParDensrel(t0, t24) 6 SEM
1.73 6 0.48 for mismatched rings and 0.23 6 0.03 for mis-
matched trophozoites) (Fig. 2C–D). Thus, misalignment be-
tween parasite and host rhythms exacerbated the stage
specificity of artemisinin.
Separating the effects of rhythm alignment and host phase
In Experiment 1, alignment co-varied with treatment during the
host’s active (dark) or resting (light) phase because upon mis-
alignment, the appearance of each IDC stage in the blood also
shifted to the opposite host phase compared to aligned infec-
tions (Fig. 1B). Therefore, we sought to determine whether the
observed differences in drug efficacy in matched and mis-
matched infections were better explained by alignment or by
host phase at the time of treatment. Statistical models in which
we replaced ‘Alignment’ with the administration of artemisinin
during the host’s active or resting phase (‘Phase’) explained
drug efficacy equally well (DAICc< 2, Table 3A). Rings were less
sensitive to artemisinin than trophozoites, and treatment dur-
ing the host’s active phase (dark) was more effective than in the
host’s resting phase (light) (StagePhase interaction: F(1,28) ¼
1.53, P¼ 0.226, Phase: F(1,29) ¼ 10.01, P¼ 0.004, Stage: F(1,29)
¼ 38.11, P < 0.001) (Table 3A). Hence, the differences in stage
specificity between matched and mismatched infections could
have equally resulted from increased artemisinin efficacy when
administered during the host’s active phase as from misalign-
ment between hosts and parasites. We employed a second ex-
periment to differentiate between these two scenarios.
Administering treatment 1 day later in Experiment 2 enabled
parasites to reschedule further. Consequently, rings in Experiment
2 could be treated during the host’s active phase for both matched
and mismatched infections, whilst all trophozoites were treated
during the resting phase (Fig. 1C). If the effects of alignment be-
tween host and parasite rhythms observed in Experiment 1 are
simply due to the effects of different host phases on drug action,
there should have been no difference in sensitivity within each IDC
stage in Experiment 2, as they were now each treated in the same
host phase. Instead, efficacy in Experiment 2 did vary significantly
according to both IDC stage and the alignment of parasite and
host rhythms (StageAlignment interaction F(1,16) ¼ 13.52,
P¼ 0.002) (Table 2A, Fig. 2E–F), revealing alignment as an
Table 2. Analyses of how drug efficacy depends on parasite intra-erythrocytic developmental cycle (IDC)
stage, the alignment of parasite and host rhythms, and putative physiological correlates
A—Drug efficacy varies with parasite IDC stage and the alignment of parasite and host rhythms
Expt. 1: log10 ParDens t24StageAlignment þ offset (log10 ParDens t0)
Stage3Alignment F(1,28) 5 10.19 P 5 0.003
Expt. 2: log10 ParDens t24StageAlignment þ offset (log10 ParDens t0)
Stage3Alignment F(1,16) 5 13.52 P 5 0.002
B—Haem levels positively correlate with drug efficacy in matched infections
Expt. 1: log10 ParDens t24StageAlignmentHaem þ offset (log10 ParDens t0)
StageAlignmentHaem F(1,23) ¼ 0.06 P¼ 0.809
StageHaem F(1,24) ¼ 0.22 P¼ 0.641
Alignment3Haem F(1,25) 5 6.24 P 5 0.019
Stage3Alignment F(1,25) 5 10.73 P 5 0.003
C—Glucose levels do not correlate with drug efficacy
Expt. 1: log10 ParDens t24StageAlignmentGlucose þ offset (log10 ParDens t0)
StageAlignmentGlucose F(1,24) ¼ 0.61 P¼ 0.441
StageGlucose F(1,25) ¼ 0.73 P¼ 0.402
AlignmentGlucose F(1,26) ¼ 0.49 P¼ 0.488
Glucose F(1,27) ¼ 1.99 P¼ 0.170
Stage3Alignment F(1,28) 5 10.19 P 5 0.003
Results of full linear statistical models including parasite densities (ParDens) at the time of drug administration (t0) and 24 h later (t24) are reported.
Terms included in the final models are in bold.
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important driver. Analogous to Experiment 1, rings in matched
infections were less sensitive than trophozoites (mean
DParDensrel(t0, t24) 6 SEM 0.566 0.05 for matched rings and
0.316 0.03 for matched trophozoites), and this difference was exa-
cerbated by mismatch (mean DParDensrel(t0, t24) 6 SEM
0.856 0.08 for mismatched rings and 0.15 6 0.04 for mismatched
trophozoites). Therefore, alignment between host and parasite
rhythms has a greater influence on IDC-stage-specific drug efficacy
than host phase per se.
Physiological correlates of stage-specific drug sensitivity
Haem concentrations at t0 in Experiment 1 ranged from 2.95 to
10.38 mM, but did not differ significantly between treatment
groups (StageAlignment interaction: F(1,27) ¼ 1.30, P¼ 0.264,
Alignment: F(1,28) ¼ 0.01, P¼ 0.941, Stage: F(1,29) ¼ 0.45,
P¼ 0.508) (Supplementary Table S4). Despite a lack of significant
between-group variation in haem levels, the statistical model
explaining drug efficacy by ‘Stage’ and ‘Alignment’ (Table 2A) was
significantly improved by the interaction between ‘Alignment’ and
‘Haem’ (AlignmentHaem interaction: F(1,25) ¼ 6.24, P¼ 0.019)
(Table 2B). Including haem levels at t0 in these analyses explained
5% more of the variance in DParDensrel(t0, t24). Haem concentra-
tions correlated positively with artemisinin efficacy for both rings
and trophozoites, but only in matched infections (Fig. 2G). When
using ‘Phase’ in the analyses, ‘Haem’ also added a significant im-
provement to the models (StagePhaseHaem interaction:
F(1,23) ¼ 5.87 P¼ 0.024) (Table 3B). However, this model did not
explain drug efficacy as well as the model including ‘Stage’,
‘Alignment’ and ‘Haem’ (DAICc¼ 7.33, Table 3B). This supports
our finding that alignment is a more important driver of IDC-
stage-specific drug efficacy than host phase.
Blood glucose concentrations at t0 in Experiment 1 ranged
from 7.7 to 12.4 mmol/L. The alignment of parasite and host
Table 3. Analyses of how drug efficacy depends on parasite intra-erythrocytic developmental cycle (IDC)
stage, host phase and putative physiological correlates
A—Drug efficacy varies with parasite IDC stage and host phase at drug administration
Expt 1: log10 ParDens t24StagePhase þ offset (log10 ParDens t0)
DAICc¼ 1.12
StagePhase F(1,28) ¼ 1.53 P¼ 0.226
Phase F(1,29) 5 10.01 P 5 0.004
Stage F(1,29) 5 38.11 P < 0.001
B—Haem levels positively correlate with drug efficacy in matched infections
Expt 1: log10 ParDens t24StagePhaseHaem þ offset (log10 ParDens t0)
DAICc¼ 7.33a
Stage3Phase3Haem F(1,23) 5 5.87 P 5 0.024
C—Glucose levels do not correlate with drug efficacy
Expt 1: log10 ParDens t24StagePhaseGlucose þ offset (log10 ParDens t0)
DAICc¼ 1.12
StagePhaseGlucose F(1,24) ¼ 0.24 P¼ 0.628
StageGlucose F(1,25) ¼ 0.50 P¼ 0.485
Stage x Phase F(1,26) ¼ 0.91 P¼ 0.349
Phase x Glucose F(1,27) ¼ 2.93 P¼ 0.098
Glucose F(1,28) ¼ 0.85 P¼ 0.365
Phase F(1,29) 5 10.01 P 5 0.004
Stage F(1,29) 5 38.11 P < 0.001
aModel with Alignment (Table 2A–C) fits better than model with Phase (Table 3A–C).
Results of full linear statistical models including parasite densities (ParDens) at the time of drug administration (t0) and 24 h later (t24) are reported.
Models presented in Table 3 correspond to models in Table 2, with the term ‘Alignment’ replaced by the term ‘Phase’. Terms included in final models
are in bold. DAICc: delta Akaike Information Criteria (corrected) compared to the associated model using ‘Alignment’ in Table 2. DAICc> 2 indicates
that models are different and the better fitting model (‘Alignment’ or ‘Phase’) is indicated.
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rhythms did not affect blood glucose concentrations
(StageAlignment interaction: F(1,28) ¼ 0.14, P¼ 0.709;
Alignment: F(1,29) ¼ 3.10, P¼ 0.089), but blood glucose was
9.6% higher when trophozoites were treated (mean concentra-
tion ¼ 10.77 6 0.23 mmol/L) compared to when rings were
treated (mean concentration ¼ 9.83 6 0.36 mmol/L) (Stage:
F(1,30) ¼ 5.00, P¼ 0.033) (Supplementary Table S5). However,
blood glucose levels did not explain any additional variance in
DParDensrel(t0, t24) of infections treated as rings or tropho-
zoites, irrespective of using ‘Alignment’ or ‘Phase’ in the analy-
ses (Tables 2C and 3C), revealing that drug efficacy was
unaffected by blood glucose concentrations at t0.
DISCUSSION
We experimentally separated parasite intra-erythrocytic develop-
mental cycle (IDC) rhythms and host rhythms in vivo and used
a fast-acting antimalarial to test their independent and interact-
ing effects on drug efficacy. Our experiments revealed three
phenomena. First, mid-ring stages of P. chabaudi are less sensi-
tive to artemisinin than mid-trophozoites. Second, alignment
between parasite and host rhythms differentially affects drug
sensitivity of rings and trophozoites; mismatch causes rings to
become less sensitive and trophozoites to become more sensi-
tive. Third, unlike blood glucose concentrations, haem levels in
the blood at the time of drug administration (t0) positively cor-
relate with artemisinin efficacy (regardless of the IDC stage
treated) but only in infections where host and parasite rhythms
are aligned.
That we find rings are less sensitive to artemisinin treatment
than trophozoites, is in keeping with other studies that also
challenge mid-rings, rather than hypersensitive very early rings
[16, 27, 32, 33] (Table 1). There are several non-mutually exclu-
sive explanations for the lower sensitivity of mid-rings. First,
low levels of haemoglobin digestion early in the IDC might
cause rings to be exposed to lower levels of haem-activated ar-
temisinin compared to trophozoites [21, 33]. Although we were
unable to detect variation in haem levels between IDC stages,
this was potentially due to high between-host variation.
Repeated measures of haem concentration from each infection
throughout an IDC might provide a more sensitive test of this
hypothesis. Second, rings may be better able to survive expos-
ure to activated artemisinins than other IDC stages (e.g. [33,
58]). For example, lower levels of ubiquitination and haemoglo-
bin digestion [20, 21] suggest rings may have an under-used
proteasome and redox buffering capacity, which they could har-
ness when faced with artemisinin-induced homeostatic imbal-
ance [59]. Furthermore, drug-induced quiescence generally
occurs at ring stage [20, 26, 27, 60], and various artemisinin-re-
sistant mutations confer enhanced protection for rings (e.g.
[61]). Perhaps IDC arrest at ring stage has evolved as a survival
strategy because the robust nature of rings means this stage is
most likely to withstand varied environmental insults.
The differential impact of the alignment between IDC stages
and host rhythms on drug sensitivity of rings versus tropho-
zoites cannot simply be explained by the effects of the host’s ac-
tive versus resting phase on drug activity. When the alignment
between parasite and host rhythms was lost, regardless of
whether treatment was administered during the host’s active or
resting phase, trophozoites became more sensitive and rings
less sensitive to artemisinin treatment, thus aggravating the
stage-specific differences in drug efficacy. Artemisinin is an im-
portant currently used antimalarial, and if our findings translate
to human malaria infections, then timing administration of this
short-acting drug against trophozoites would maximise efficacy.
The World Health Organisation recommends artemisinin com-
bination therapy to be administered for 3 days against the
human malaria parasite P. falciparum [62, 63], which has a 48-h
IDC (reviewed in [10]). Whilst we would not advocate withhold-
ing treatment from ill patients, it might be beneficial to ensure
2 of the 3 days are timed to target trophozoites. If novel drugs
can be developed to disrupt the alignment between the IDC
schedule and host rhythms (e.g. by modulating nutrient sensing
by the parasite [64]), then administering such drugs alongside
the first dose of traditional antimalarials might render subse-
quent doses targeting trophozoites, more effective.
Finding targets for IDC-schedule-disrupting drugs will be
facilitated by understanding why mismatch exacerbates stage-
specific differences in drug sensitivity. Clues could lie in the
altered gene expression patterns recently uncovered in mis-
matched P. chabaudi parasites [57]. This includes genes
involved in DNA replication, oxidation-reduction processes, ubi-
quitin-mediated proteolysis and proteasome pathways and en-
ergy metabolism [57]. Many of these pathways are also linked to
artemisinin resistance, for example: (i) proteasome inhibitors
synergise artemisinin efficacy [20, 65]; (ii) a delayed progression
through the IDC protects parasites from various drugs includ-
ing artemisinins [20, 24, 26, 27, 40, 60]; (iii) nutrient limitation
can prolong the maturation period of rings in vitro [66, 67],
whilst disproportionally affecting artemisinin-tolerant parasites
that rely more on exogenous amino acids to mature from rings
to trophozoites [68]; and (iv) transcriptional profiles of P. falcip-
arum lines selected for artemisinin resistance show transcrip-
tional changes for similar pathways [23, 69].
Although studies of chronotherapy against infections are
scarce, diurnal changes in drug efficacy have been observed for
both fungal and bacterial infections. Treatment of Candida albi-
cans was most effective in the resting phase of mice [70], where-
as E. coli in rats was best killed during the active phase [71]. In
both studies, the impact of timing faded when higher drug
doses were used, perhaps indicating the importance of chrono-
therapy in cases where drug doses are constrained due to
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toxicity or when pathogens are not completely cleared by
drugs—for example when combatting partially resistant popula-
tions. When seemingly adequately applied antimalarials do not
immediately eliminate all parasites [72], sublethal drug doses
may minimise selection for resistance [73] and virulence [74]. In
addition, such doses may maximise the impact of chronother-
apy on parasite clearance alongside its potential benefits in
reducing drug toxicity [75].
Precise timing of drug administration could also affect effi-
cacy via downstream effects on the immune system. In a mur-
ine bone injury model, drug administration during the active
period promoted anti-inflammatory cytokines over a pro-inflam-
matory response, and in turn resulted in improved healing,
compared to treatment during the resting period [76]. By the
same token, chronotherapy for COVID-19 has been suggested,
with the aim to attenuate the typically detrimental inflammatory
cascade in patients in the afternoon and evening, without inter-
fering with the beneficial inflammatory response during the day
[77]. Artemisinin derivatives attenuate pro-inflammatory im-
mune responses (reviewed in [78]), which could be harnessed
to mitigate the pathology associated with schizogony-induced
inflammation (reviewed in [79]). Treating mid-to-late tropho-
zoites could thus be doubly helpful: parasites would be targeted
at their most vulnerable IDC stage, and this occurring shortly
before schizogony could maximise artemisinin’s immunosup-
pressive properties against the impeding cytokine storm caused
by any surviving parasites.
CONCLUSIONS AND IMPLICATIONS
Our experiments were performed in vivo using a nocturnal host
and the rodent malaria parasite P. chabaudi, which has a 24-h
intra-erythrocytic developmental cycle (IDC). Care should be
taken when extrapolating results to human malaria, among
others because P. falciparum has a 48-h IDC and humans are
not nocturnal. However, like P. chabaudi, many genes of P. fal-
ciparum are transcribed with 24-h periodicity [57], including
genes involved in processes that lose rhythmicity in misaligned
infections in P. chabaudi, and have been implicated in artemisi-
nin resistance in both rodent malarias and P. falciparum (e.g.
carbohydrate metabolism, DNA replication and the ubiquitin
proteasome system [23, 57, 69]). Furthermore, like mice,
humans also have active and resting phases, and misalignment
between host and P. falciparum IDC rhythms can occur, with
infections even becoming asynchronous. When uncomplicated
malaria cases are diagnosed, information on host internal time
as well as parasite IDC stage distribution and synchronicity
could be collected by microscopy [80] or qPCR [81] to infer the
timing of the IDC rhythm and determine when parasites are
best targeted. The impact of chronotherapy should be most pro-
nounced in highly synchronous infections, when multi-day
treatment regimens repeatedly target the same IDC stage in
subsequent replication cycles [13, 82], and when parasite and
host rhythms are naturally or forcefully misaligned. Finally, if
timed treatment is not achievable, then extending artemisinin
combination therapy to include not 3 (1.5 IDCs) but 4 days (2
IDCs) would make treatment efficacy less dependent on the
sensitivity of the parasite IDC stage that happens to predomin-
ate at the start of treatment [13, 20, 58, 82].
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